Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

The UK MHRA has approved AstraZeneca's Trixeo Aerosphere inhaler to treat adults with chronic obstructive pulmonary disease ...

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.

Minghui Pharmaceutical has announced an exclusive licensing and partnership agreement with Qilu Pharmaceutical for MHB088C in ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...